GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (£4.0 billion)

 GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (£4.0 billion)

GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (£4.0 billion)

Shots:

  • GSK to acquire Tesaro, in all stock transaction with its Zejula and preclinical candidates. Tesaro to get $75/share in cash for a premium of 62% with total deal value of $5.1B
  • The focus of acquisition is to build oncology portfolio with Tesaro’s products for targeting multiple cancers including ovarian, lung and prostate cancer. In March 2015, GSK divested its oncology portfolio related R&D activities, AKT inhibitor rights and commercialization partner rights to Novartis
  • Zejula (niraparib) PO is a poly ADP ribose polymerase (PARP) inhibitor for ovarian cancer and is approved for adults with recurrent ovarian cancer + Pt-based CT in the US and EU in 2017

Click here to read full press release/ article | Ref: GSK | Image: GSK

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post